ENVALITH
株式会社FRONTEO logo

FRONTEO, Inc.

2158・Growth Market・Services

Official website
株式会社FRONTEO logo
FRONTEO, Inc.2158

Business

FRONTEO, Inc. develops businesses across three segments—Life Science AI (AI drug discovery and AI medical devices), Risk Management (digital forensics investigation, compliance support, and economic security), and DX (DX solutions for the manufacturing industry)—centered on its proprietary equation-driven AI "KIBIT" as core technology. Its main customers include major pharmaceutical companies, biotech ventures, financial institutions, legal and compliance departments of major corporations, and government agencies. Consolidated net sales for FY2026 (ending March 2026) were ¥7,643 million, driven by the full-scale contribution of the DX segment following the consolidation of Arnetz as a subsidiary and the rapid expansion of the AI drug discovery field.

Business Model

In the risk management business, the core revenue drivers are commissioned projects for forensic investigations and compliance audits utilizing KIBIT, together with recurring SaaS revenue. In the AI drug discovery field, in addition to upfront revenue from co-creation projects, the company is advancing a structural shift toward success-based revenue such as milestone payments, royalties, and license-out lump sums. In the AI medical device field, the company expects milestone fees and post-launch royalties from joint development with Shionogi & Co., Ltd. The DX business creates added value through cross-selling of Arnetz's Mendix platform and KIBIT.

Company Strengths

Using DDAIF, the company extracted 17 candidate target molecules from approximately 20,000 genes within two days, and demonstrated that 4 of these genes were novel candidates with no related published papers. As of the end of December 2025, DDAIF-related patents totaled 23 worldwide. The company has a track record of concurrently advancing co-creation projects with more than 10 major pharmaceutical companies, including EA Pharma, Chugai Pharmaceutical, Daiichi Sankyo, and Santen Pharmaceutical.

"KIBIT Eye" has achieved a 100% adoption rate among megabank groups and an 80% adoption rate among the five major securities companies. New adoptions during the current fiscal year at Mizuho Securities and Shinkin Central Bank have also been confirmed, and the accumulation of years of track record and specialized expertise makes short-term imitation by competitors difficult. It functions as a stable foundation for recurring revenue.

The company possesses high credibility backed by its track record of adoption by third-party committees and special investigation committees. FRONTEO Legal Link Portal has achieved 20,000 registered members and over 1,000 published videos, and in January 2026 established the Risk Initiative Community. The company maintains stable order intake through continuous strengthening of customer touchpoints.

ENVALITH's Perspective

In FY2026 (ending March 2026), the company achieved increased revenue and profit, with net sales of ¥7,643 million (up 25.3% year on year) and operating profit of ¥739 million (up 40.1% year on year). However, the company forecast for FY2027 (ending March 2027) anticipates net sales of ¥7,600 million (down 0.6% year on year) and operating profit of ¥300 million (down 59.4% year on year), a significant decline in profit. Continued upfront investment in the Life Science AI business and structural transformation costs in the Risk Management business are expected to weigh on profit. The pace of accumulation of co-creation projects in the AI drug discovery field and the timing of realization of milestone revenue will be key to the stock valuation.

Following the acquisition of Alnetz (acquisition cost of ¥1,554,999 thousand), short-term borrowings expanded to ¥2,600 million and long-term borrowings to ¥957 million, causing the equity ratio to decline from 45.9% in the prior period to 39.7%. The interest coverage ratio also fell sharply from 36.7x in the prior period to 6.5x, and the increase in interest-bearing debt could become a financial constraint. Meanwhile, goodwill of ¥1,039 million (amortized on a straight-line basis over 15 years) was recorded, and the resulting amortization burden will continue going forward. Operating cash flow declined significantly to ¥321 million from ¥753 million in the prior period, and free cash flow turned negative, which also warrants attention.

Net sales for the Risk Management business overall declined significantly to ¥4,020 million (down 25.2% year on year), mainly due to the contraction of the Legal Tech AI field (down 38.8% year on year) resulting from the withdrawal of a US subsidiary's business, a factor with a large one-off impact. Meanwhile, in the Economic Security field, orders remained solid amid heightened geopolitical risk as an external factor, with net sales of ¥546 million (up 28.2% year on year), maintaining growth. The Compliance Support field is pursuing a policy of strategic selection and focus, accepting a short-term decline in sales while working to strengthen its recurring revenue base.

Growth Strategy

With the Life Science AI business positioned as its core, the company aims to achieve Stage 4 of its medium-term management plan by FY2029 (ending March 2029)

The company is combining four models—co-creation projects, comprehensive co-creation model, DDAIF Innovation Bridge, and proprietary research—to drive a shift from short-term contract revenue toward mid- to long-term milestone and royalty revenue. In the current period, sales in the AI drug discovery field surged 511.7% year-on-year, and the operating loss of the Life Science AI business narrowed to ¥16 million. Profitability is expected to be achieved in FY2027 (ending March 2027), driven by growth in the drug discovery business.

The "Conversational AI Program Medical Device for Cognitive Function Testing (SDS-881)," jointly developed with Shionogi & Co., Ltd., has already been designated as a priority review item by the Ministry of Health, Labour and Welfare. Clinical trials began in May 2025, and the company aims to obtain approval within FY2026. Upon approval, the company expects to receive milestone fees and royalty fees, contributing to the establishment of a mid- to long-term revenue base.

By combining Arnetz's low-code platform "Mendix" implementation support capabilities—Arnetz became a wholly owned subsidiary in April 2025—with FRONTEO's "KIBIT" as an add-on, the company is creating added value and promoting cross-selling to the manufacturing customer base. DX business sales for the current period increased substantially to ¥2,590 million (up 598.9% year-on-year). From FY2027 (ending March 2027), the DX business segment will transition to a structure comprising Arnetz alone.

Through a strategic partnership agreement with U.S. consulting firm Q Partners LLC and the commencement of joint research with the University of Oklahoma, the company is advancing full-scale expansion of its AI drug discovery business into the U.S. market. By establishing a joint research base at Institute of Science Tokyo, the company aims to build an integrated research system spanning hypothesis generation through experimental verification, with the goal of creating highly novel drug discovery pipelines.

The company is expanding its supply chain analysis and shareholder control network analysis solutions utilizing "KIBIT Seizu Analysis." In the current period, orders from government agencies and companies progressed steadily, including implementation at Sumitomo Heavy Industries, Ltd. and the receipt of an order for the Cabinet Office's "Support Project for Establishing a Risk Management System Related to Research Security and Integrity," resulting in sales of ¥546 million (up 28.2% year-on-year).

Last updated: July 19, 2026